Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track APGE with free AI briefings, catalyst countdowns, and dilution alerts.

APGE · Apogee Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.3B Cash on Hand

61.2mo Cash Runway

7.3% Short Interest

$134.62 Analyst Target (5)

Follow APGE by email Get an email when APGE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about APGE, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Nov 2026 · Phase 2 · Active Trial · A Study Evaluating APG777 in Atopic Dermatitis
Registry primary completion date, not a results date
Dec 2029 · Phase 2 · Recruiting · A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Opaganib (ABC294640)	Carcinoma, Hepatocellular	Phase 2 · NCT02939807	Withdrawn
APG777	Atopic Dermatitis	Phase 2 · NCT06395948	Active not recruiting
APG990	Atopic Dermatitis	Phase 1 · NCT07027527	Active not recruiting

Also used in these trials (approved or third-party drugs, not APGE's own candidates): Dupilumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

APGE holds $1.3B in cash and short-term investments (as of Jun 30, 2026) and burns about $63.5M/quarter from operations, an estimated runway of 61.2 months at that rate (BioRadar estimate, not company guidance).

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when APGE files for a raise →

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-09-03 filed 2026-09-03	Fairmount Funds Management L	Returned to issuer (D)	14,461	–	–
2026-09-03 filed 2026-09-03	McKenna Mark C.	Returned to issuer (D)	20,000	–	0
2026-09-03 filed 2026-09-03	Shah Nimish P	Returned to issuer (D)	365,853	–	–
2026-09-03 filed 2026-09-03	Shah Nimish P	Returned to issuer (D)	7,657	–	–
2026-09-03 filed 2026-09-03	Shah Nimish P	Returned to issuer (D)	14,461	–	–

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full APGE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APGE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z